Definitive Contract 75F40122C00147
Award Date
9/26/22
Potential Completion Date
3/31/26
Potential Value
$400K
Federal Agency
Food and Drug Administration
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Silver Spring, MD 20993, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
165
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $3,526,785.00 definitive, firm fixed-price contract awarded by the Food and Drug Administration (FDA) to the Regents of the University of Michigan, doing business as the University of Michigan, for Prediction of In Vivo Performance Analysis Services. The contract has no set-aside designation. The University of Michigan is providing a range of research and development services under this contract, including developing high-performance computational models to simulate small intestine...
The Department of Health and Human Services' Food and Drug Administration (FDA) awarded a $1,151,037 firm-fixed-price contract to the Regents of the University of Michigan for the development of "SEAMLESS DESIGN FOR MULTICOMPONENT ENDPOINTS FOR DRUG DEVELOPMENT IN RARE DISEASES." This definitive contract, which has a completion date of September 29, 2026, does not have a set-aside designation. The University of Michigan, a prominent U.S. state government-owned educational...
The U.S. Food and Drug Administration (FDA) awarded a $1,000,000.00 definitive contract to the Regents of the University of Michigan to conduct research on the "Influence of Raw Materials Manufacturing Variables and Storage Conditions on Release Performance of Long Acting Release Microsphere Products." This is a cost-no-fee contract with a completion date of September 29, 2019. The University of Michigan is a U.S. Government Entity providing educational services and has extensive...
The Department of Health and Human Services Food and Drug Administration awarded a definitive cost-no-fee contract to the Regents of the University of Michigan for $1,482,306.00. The contract is to conduct research on the influence of raw materials, manufacturing variables, and storage conditions on the release performance of long-acting release microsphere products. The contract does not have a set-aside designation. The University of Michigan is a U.S. state government educational...
The Department of Health and Human Services' Food and Drug Administration awarded a $797,837.04 definitive cost-no-fee contract to the Regents of the University of Michigan (doing business as the University of Michigan) for the PMWP#112 - Innovative Randomized Drug Trial Design Bayesian Analysis project. The contract, which does not have a set-aside designation, is for the development of analyses to support small-sample, sequential, multiple assignment randomized trials for the registration of a...
This is a federal contract award from the Food and Drug Administration (FDA) to the Regents of the University of Michigan (University of Michigan) for the development of a "Wireless Pharmaceutical Analysis Device (WPAD) and Computational Model to Determine In Vivo Drug Dissolution in GI Tract for Distinguishing Meaningful Product Differences and Ensuring Bioequivalence." The contract is a definitive contract with a cost-no-fee pricing type and has a ceiling value of $6,343,667.39....
The Food and Drug Administration (FDA) awarded a firm-fixed-price purchase order contract valued at $51,942.80 to the Regents of the University of Michigan to provide DNA isolation and 16S rRNA sequencing for microbiome analysis of murine (mouse) fecal samples. The contract has a period of performance through March 27, 2024. This requirement was sole-sourced to the University of Michigan, which has extensive experience providing research and development services to federal agencies including the...
The Food and Drug Administration (FDA) awarded a $997,608 firm-fixed-price contract to the Regents of the University of Michigan to conduct research and development on the characterization of Exparel, understanding of critical manufacturing process parameters, and characterization of drug release mechanisms in vitro and in vivo. This contract was awarded under a Broad Agency Announcement solicitation that the FDA renews annually to advance scientific knowledge in support of its mission to...
This federal contract, awarded by the Food and Drug Administration (FDA) to the Regents of the University of Michigan, is a $2,235,290.00 firm fixed-price definitive contract to conduct a comprehensive study on stimulant and opioid use and use disorder trajectories and associated consequences in U.S. adults. The contract does not have a set-aside designation. The University of Michigan, as the prime contractor, will leverage its extensive research capabilities to carry out this study. Two...
This $7,369,588 federal contract was awarded by the Food and Drug Administration (FDA) to the Regents of the University of Michigan. The contract is titled "In Vivo Predictive Dissolution (IPD) to Advance Oral Product Bioequivalence (BE) Regulation" and aims to develop improved methods for assessing the bioequivalence of oral drug products. The contract has three main objectives: 1) Mass transport analysis of the gastrointestinal tract, 2) Development and validation of gastrointestinal...